Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: Effects of subthalamotomy and levodopa treatment

Brain Research

Volumn 1084, Issue 1, 2006, Pages 175-184

  Bilbao, Gaizka ^a   Ruiz Ortega, Jose Angel ^b   Miguens, Natalia ^b   Ulibarri, Isabel ^b   Linazasoro, Gurutz ^c   Gómez Urquijo, Sonia ^b   Garibi, Jesús ^a,b   Ugedo, Luisa ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Policlinic of Gipuzkoa ^*  (Spain)

Author keywords

Apomorphine; Extracellular recording; Parkinson's disease; Responsiveness; Tyrosine hydroxylase

Indexed keywords

APOMORPHINE; BENSERAZIDE; IBOTENIC ACID; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; MALE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ACTION POTENTIALS; ADRENERGIC AGENTS; ANIMALS; APOMORPHINE; BRAIN INJURIES; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; NEURONS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 33646425853     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.02.052     Document Type: Article

References (44)

1. Agid Y., Javoy F., and Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat. New Biol. 245 (1973) 150-151
2. Akaoka H., Charlety P., Saunier C.F., Buda M., and Chouvet G. Inhibition of nigral dopamine neurons by systemic and local apomorphine: possible contribution of dendritic autoreceptors. Neuroscience 49 (1992) 879-891
3. Alvarez L., Macias R., Lopez G., Alvarez E., Pavon N., Rodriguez-Oroz M.C., Juncos J.L., Maragoto C., Guridi J., Litvan I., Tolosa E.S., Koller W., Vitek J., DeLong M.R., and Obeso J.A. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain 128 (2005) 570-583
4. Benazzouz A., Piallat B., Hoffmann D., Limousin P., Gao M., Pollack P., and Benabid A. Microrecordings of subthalamic nucleus and substantia nigra pars reticulata neuronal activity in parkinsonian patients. Mov. Disord. 11 Suppl. 1 (1996) 77
5. Bergman H., Wichmann T., Karmon B., and DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72 (1994) 507-520
6. Bergstrom B.P., and Garris P.A. "Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat. J. Neurochem. 87 (2003) 1224-1236
7. Bezard E., Boraud T., Bioulac B., and Gross C.E. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81 (1997) 399-404
8. Bezard E., Boraud T., Bioulac B., and Gross C.E. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11 (1999) 2167-2170
9. Bezard E., Crossman A.R., Gross C.E., and Brotchie J.M. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J. 15 (2001) 1092-1094
10. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., and Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001) 6853-6861
11. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26 (2003) 215-221
12. Bokobza B., Ruberg M., Scatton B., Javoy-Agid F., and Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 99 (1984) 167-175
13. 125 I] iodosulpiride. Neuroscience 20 (1987) 117-155
14. Carlsson T., Winkler C., Burger C., Muzyczka N., Mandel R.J., Cenci A., Bjorklund A., and Kirik D. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous l-DOPA delivery using rAAV vectors. Brain 128 (2005) 559-569
15. Chergui K., Akaoka H., Charlety P.J., Saunier C.F., Buda M., and Chouvet G. Subthalamic nucleus modulates burst firing of nigral dopamine neurones via NMDA receptors. NeuroReport 5 (1994) 1185-1188
16. Chergui K., Suaud-Chagny M.F., and Gonon F. Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 62 (1994) 641-645
17. Chritin M., Blanchard V., Raisman-Vozari R., Feuerstein C., Agid Y., Javoy-Agid F., and Savasta M. DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration. Eur. J. Neurosci. 8 (1996) 2511-2520
18. Dentresangle C., Le Cavorsin M., Savasta M., and Leviel V. Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra. Brain Res. 893 (2001) 178-185
19. Doroudchi M.M., Liauw J., Heaton K., Zhen Z., and Forsayeth J.R. Adeno-associated virus-mediated gene transfer of human aromatic l-amino acid decarboxylase protects mixed striatal primary cultures from l-DOPA toxicity. J. Neurochem. 93 (2005) 634-640
20. Ferrario J.E., Delfino M.A., Stefano A.V., Zbarsky V., Douhou A., Murer M.G., Raisman-Vozari R., and Gershanik O.S. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci. Res. 47 (2003) 431-436
21. Galeffi F., Bianchi L., Bolam J.P., and Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci. 18 (2003) 856-868
22. Grace A.A., and Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 10 (1983) 301-315
23. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4 (1984) 2877-2890
24. Hollerman J.R., and Grace A.A. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res. 533 (1990) 203-212
25. Hutchison W.D., Levy R., Dostrovsky J.O., Lozano A.M., and Lang A.E. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. 42 (1997) 767-774
26. Iribe Y., Moore K., Pang K.C., and Tepper J.M. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J. Neurophysiol. 82 (1999) 925-933
27. Knyihar-Csillik E., Csillik B., Pakaski M., Krisztin-Peva B., Dobo E., Okuno E., and Vecsei L. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience 126 (2004) 899-914
28. Macarrone M., Gubellini P., Bari M., Picconi B., Battista N., Centoze D., Bernardi G., Finazzi-Agrò A., and Calabresi P. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85 (2003) 1018-1025
29. Mytilineou C., Walker R.H., JnoBaptiste R., and Olanow C.W. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304 (2003) 792-800
30. Ni Z., Gao D., Bouali-Benazzouz R., Benabid A.L., and Benazzouz A. Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway. Eur. J. Neurosci. 14 (2001) 373-381
31. Nilsson M.H., Tornqvist A.L., and Rehncrona S. Deep-brain stimulation in the subthalamic nuclei improves balance performance in patients with Parkinson's disease, when tested without anti-parkinsonian medication. Acta Neurol. Scand. 111 (2005) 301-308
32. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernas H., Nystrom C., and Aquilonius S.M. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol. 26 (2003) 156-163
33. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Annu. Rev. Med. 55 (2004) 41-60
34. Parker R.B., and Waud D.R. Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. J. Pharmacol. Exp. Ther. 177 (1971) 1-12
35. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1996), Academic Press, Orlando
36. Pucak M.L., and Grace A.A. Partial dopamine depletions result in an enhanced sensitivity of residual dopamine neurons to apomorphine. Synapse 9 (1991) 144-155
37. Rajput A.H. The protective role of levodopa in the human substantia nigra. Adv. Neurol. 86 (2001) 327-336
38. Rodriguez Diaz M., Alonso T.J., Perdomo Diaz J., Gonzalez Hernandez T., Castro Fuentes R., Sabate M., and Garcia Dopico J. Glial regulation of nonsynaptic extracellular glutamate in the substantia nigra. Glia 49 (2005) 134-142
39. Ruiz-Ortega J.A., Linazasoro G., and Ugedo L. Differential effects of dopamine agonists on subthalamic neurons in intact and 6-OH-dopamine treated parkinsonian rats. Fundam. Clin. Pharmacol. 15 Suppl. 1 (2001) 9P015
40. Smith I.D., and Grace A.A. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 12 (1992) 287-303
41. Tintner R., and Jankovic J. Treatment options for Parkinson's disease. Curr. Opin. Neurol. 15 (2002) 467-476
42. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand., Suppl. 367 (1971) 1-48
43. Vila M., Perier C., Feger J., Yelnik J., Faucheux B., Ruberg M., Raisman-Vozari R., Agid Y., and Hirsch E.C. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur. J. Neurosci. 12 (2000) 337-344
44. Zigmond M.J., Hastings T.G., and Perez R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism Relat. Disord. 8 (2002) 389-393